Abstract
Obesity-related conditions are among the leading causes of preventable death and are increasing in prevalence worldwide. Body size and composition are complex traits that are challenging to characterize due to environmental and genetic influences, longitudinal variation, heterogeneity between sexes, and differing health risks based on adipose distribution. We constructed a 4-factor genomic structural equation model using 18 measures and unveiled shared and distinct genetic architectures underlying birth size, abdominal size, adipose distribution, and adiposity. Multivariate genome-wide associations revealed the adiposity factor was enriched specifically in neural tissues and pathways, while adipose distribution was enriched across widespread physiological systems. In addition, polygenic scores for the adiposity factor predicted many adverse health outcomes, while body size and composition predicted a more limited subset. Finally, we characterized the factors’ genetic correlations with obesity-related traits and examined the druggable genome through constructing a bipartite drug-gene network to identify viable therapeutic targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CHA was supported by the IBG NIMH T32MH016880 training grant and by the Interdisciplinary Quantitative Biology program. RAG was supported by the University of Colorado Boulder's Summer Multicultural Access to Research Training program, part of the Colorado Diversity Initiative, which is funded internally by the University of Colorado Boulder Graduate School. MAS was supported by grant K01 HL157658. ADG was supported by NIH Grants R01MH120219 and RF1AG073593. LME was supported by R01AG046938.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Board at the University of Colorado Boulder deemed that institutional review board approval was not necessary for our analyses as GWAS summary data do not include individual-level results; the studies that published the incorporated summary statistics obtained written informed consent from participants and were approved by ethics committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data included in this study were publicly available and citations linking downloads to the GWAS summary statistic files are included in the supplementary information. Multiavariate GWAS summary statistics for the 4 genetic factors will be made publicly available with the publication of this manuscript along with the LDpred2-derived PRS weights.
